# OMega-3 Fatty Acid for the Immune Modulation of Colorectal Cancer

> **NCT03661047** · PHASE2 · WITHDRAWN · sponsor: **Massachusetts General Hospital**

## Conditions studied

- Colon Cancer

## Interventions

- **DRUG:** AMR101 (VASCEPA, icosapent ethyl)

## Key facts

- **NCT ID:** NCT03661047
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-11-30
- **Primary completion:** 2021-11-30
- **Final completion:** 2021-11-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study will be closed due to zero enrollment in over 2 years.
- **Last updated:** 2021-11-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03661047

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03661047, "OMega-3 Fatty Acid for the Immune Modulation of Colorectal Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03661047. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*